A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Melanoma, Bladder Cancer, Nsclc, Urothelial Carcinoma
-
Age: Between 18 years - 99 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- 1. Histologically confirmed locally advanced or metastatic melanoma, locally advanced or metastatic urothelial carcinoma, or metastatic non-small cell lung cancer (NSCLC)
- 2. Patients must not have received prior interleukin-2 (IL-2) therapy
- 3. Significant toxic effect(s) of the most recent prior chemotherapy must be
resolved (except alopecia and sensory neuropathy).
You may not be eligible for this study if the following are true:
-
- 1. Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s)
- 2. Patients who have an active, known or suspected autoimmune disease
- 3. History of allergy or hypersensitivity to study drug components.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.